Home » In The News » Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100
We use cookies to store and access device information so we can provide you with the best possible web experience. Your consent allows us to process data such as your browsing behaviour. Disabling cookies may adversely affect some of our website’s features and functions.
Due to slower mail processing times, mailed donations may take longer than usual to reach us. Discover other easy and convenient ways to donate in support of the JGH.